Uptake of I-125 radiolabelled dynorphin in glioma cell cultures

1996 ◽  
pp. 337-341
Author(s):  
H. Wolf ◽  
S. Tinnemeyer ◽  
A. Brandt ◽  
W. Brenner ◽  
C. Stauch ◽  
...  
Keyword(s):  
2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15045-e15045
Author(s):  
Irina V. Mezhevova ◽  
Svetlana Yu. Filippova ◽  
Sofia V. Timofeeva ◽  
Anastasia O. Sitkovskaya ◽  
Tatiana V. Shamova ◽  
...  

e15045 Background: Berberine is an alkaloid compound with a structure that is highly similar to that of intercalating agents. It affects numerous cell signaling pathways and is widely studied as potential anticancer drug. It is known that berberine affects cancer cells migration through metalloproteinase-2 inhibition, but this effect was never studied on glioma cells. Anti-migratory drugs are of special interest in brain cancer therapy since glioma's highly invasive nature makes total surgical removal of tumor practically impossible. The aim of the study was to evaluate berberine anti-migratory activity on glioma cells. Methods: Cell migration capacity of T98G and U87MG cell lines, as well as primary glioma cell culture established in our laboratory, was assessed via standard wound healing assay with automated image acquisition and analysis on Lionheart FX (BioTek) cell imager. Prior to assay setting up cell cultures were maintained in DMEM medium with L-glutamine (1 μM) (Gibco) and 10% FBS (Gibco) at 37C0 and 5.0% CO2. Cells were seeded at 250 000 cells per well on 24-well plates and incubated overnight in order to attach to plate bottom. After that a vertical wound was made manually in each well, and berberine was added to experimental wells to final concentration 50 mg/L. Plates with cells were continuously incubated and photographed in cell imager at 37C0 and 5.0% CO2. The extent of cells migration was measured as the percent of wound area decrease after 24 hours of incubation in relation to starting time point. Data are given as: Mean ± 95% confidence interval. Results: In our study we berberine exhibited anti-migratory activity in all cell cultures under study. In rather fast growing primary cell culture wound area decrease was 99.23%±0.62% in control sample and 91.75%±0.28% in experimental sample. The difference was small but significant at p < 0.001 level (df = 30). Popular permanent glioma cell lines T98G and U87MG showed more prominent decrease in studied parameter with higher degree of variance at the same time. In T98G wound area decrease was 71.6%±12.3% in control and 48.8%± 7.6% in experimental samples after 24 hours of cultivation in presence of 50 mg/L berberine. While U87MG demonstrated 60.28%±5.13% and 37.5%± 8.34% wound area decrease accordingly. The obtained difference between control and experimental groups in permanent cell cultures was statistically significant at the 0.05 level (df = 30). Conclusions: Our preliminary research proved berberine to be potent anti-migratory agent in glioma treatment. Further investigations are needed to evaluate its ability to inhibit glioma cell expansion in vivo.


1988 ◽  
Vol 76 (5) ◽  
pp. 433-440 ◽  
Author(s):  
K. Onda ◽  
R. Tanaka ◽  
K. Washiyama ◽  
N. Takeda ◽  
T. Kumanishi

2013 ◽  
Vol 113 (2) ◽  
pp. 239-249 ◽  
Author(s):  
Marie-France Nissou ◽  
Michèle El Atifi ◽  
Audrey Guttin ◽  
Catherine Godfraind ◽  
Caroline Salon ◽  
...  

2015 ◽  
Vol 49 (5) ◽  
pp. 296-300 ◽  
Author(s):  
I. S. Khazhieva ◽  
T. V. Glukhareva ◽  
O. S. El’tsov ◽  
Yu. Yu. Morzherin ◽  
A. A. Minin ◽  
...  

2019 ◽  
Vol 19 (3) ◽  
pp. 206-214 ◽  
Author(s):  
Chiara Cioni ◽  
Maristella Tassi ◽  
Giuseppe Marotta ◽  
Claudia Mugnaini ◽  
Federico Corelli ◽  
...  

Background: Cannabinoid receptors have been detected in human gliomas and cannabinoids have been proposed as novel drug candidates in the treatment of brain tumors. Aims: To test the in vitro antitumor activity of COR167, a novel cannabinoid CB2-selective agonist displaying a high binding affinity for human CB2 receptors, on tumor cells isolated from human glioblastoma multiforme and anaplastic astrocytoma. Methods: Glioma cell cultures were established from two glioblastoma multiforme and two anaplastic astrocytomas. Proliferation was measured in the presence or absence of COR167 with a bromodeoxyuridine (BrdU) cell proliferation ELISA assay. CB2 receptor expression was detected by western blotting. Apoptosis was assessed with phycoerythrin (PE) annexin V flow cytometry kit. TGF-beta 1 and 2 levels were analyzed in culture supernatants with commercial ELISAs. Results: COR167 was found to significantly reduce the proliferation of both glioblastoma and anaplastic astrocytoma in a dose-dependent manner at lower doses than other known, less specific CB2 agonists. This activity is independent of apoptosis and is associated with a significant reduction of TGF-beta 1 and 2 levels in supernatants of glioma cell cultures. Conclusion: These findings add to the role of cannabinoid CB2 receptor as a possible pharmacological target to counteract glial tumor growth and encourage further work to explore any other pharmacological effect of this novel CB2 agonist useful in the treatment of human gliomas.


2000 ◽  
Vol 126 (12) ◽  
pp. 711-716 ◽  
Author(s):  
Fabian Fehlauer ◽  
Angeliqué D. Barten-Van Rijbroek ◽  
Lukas J. A. Stalpers ◽  
Sieger Leenstra ◽  
Jan Lindeman ◽  
...  

1987 ◽  
Vol 16 (1) ◽  
pp. 45-46
Author(s):  
B. Dipasquale ◽  
M. Colombatti ◽  
P. Lorenzi ◽  
G. Stevanoni ◽  
P. Germano ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document